Bladder cancer in patients after organ transplantation

Current Opinion in Urology

Volumn 20, Issue 5, 2010, Pages 432-436

  Wallerand, Hervé ^a   Ravaud, Alain ^b   Ferrière, Jean Marie ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

Author keywords

bladder neoplasm; MTOR inhibitors; renal transplantation

Indexed keywords

BCG VACCINE; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

AGE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER TUMOR; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER SCREENING; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77955468128     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32833cf1ef     Document Type: Review

References (38)

1. Vadjic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823-2831.
2. Jensen A, Thomsen H, Engebjerg M, et al. Use of oral glucocorticoids and risk of skin and non-Hodgkin's lymphoma: A population-based case-control study. Br J Cancer 2009; 100:200-205.
3. Dietrich K, Schned A, Fortuny J, et al. Glucocorticoids therapy and risk of bladder cancer. Br J Cancer 2009; 101:1316-1320.
4. Elkentaoui H, Robert G, Pasticier G, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: The experience of the French department of urology and kidney transplantation from Bordeaux. Urology 2010; 75:126-132. This recent study reports 42 de-novo urological neoplasms in renal transplant recipients in which the authors described five bladder tumors with aggressive clinical outcomes. It highlights the fact that BCG therapy seems reasonable but argues for a strict surveillance of these patients.
5. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organs transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009; 87:1347-1359. This article confirms that neoplasms in organ transplant recipients (lung cancer, breast cancer, prostate cancer, bladder cancer, renal cell cancer, and melanoma) are more aggressive biologically. This study is interesting as it concerns different human epithelial neoplasm in transplant recipients.
6. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346:403-406.
7. Sheil AG, Disney AP, Mathew TH, et al. Lymphoma incidence, cyclosporine and the evolution and major impact of malignancy following organ transplantation. Transplant Proc 1997; 29:825-827.
8. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries. Int J Cancer 1995; 60:183-189.
9. Berger AD, Kubak BM, Shpiner RB, et al. Transitional cell carcinoma of the bladder two years after successful lung transplantation: Case report and review of the literature. Urology 2002; 59:296xiii-296xiv.
10. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology 1997; 50:525-528.
11. Master VA, Meng MV, Grossfeld GD, et al. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004; 171: 1085-1088.
12. Tosaka A, Ohya K, Yamada K, et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol 1990; 144:1097-1099.
13. Li XB, Xing NZ, Wang Y, et al. Transitional cell carcinoma in renal transplant: A single center experience. Int J Urol 2008; 15:53-57.
14. Nortier JL,Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia frangchi). N Engl J Med 2000; 342:1686-1692.
15. Wu M, Lian J, Yang C, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kideney Dis 2004; 43:1091-1097.
16. Tremblay F, Fernandes M, Habbab F, et al. Malignancy after renal transplantation incidence and role of type of immunosuppression. Ann Surg Oncol 2002; 9:785-788.
17. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530-534.
18. Kleinclauss F, Gigante M, Neuzillet Y, et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008; 23:2374-2380.
19. Sorensen H, Mellemkjaer L, Nielsen G, et al. Skin cancers and non-Hogkin lymphoma among users of systemic glucorcorticoids: A population-based cohort study. J Natl Cancer Inst 2004; 96:709-711.
20. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
21. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77:1319-1326.
22. Campistol JM, Eris J, Oberbauer P, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-589.
23. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. Engl J Med 2005; 352:1371-1373.
24. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
25. Okada T, Sawada T, Kubota K. Rapamycin enhances the antitumor effect of gemcitabine in pancreatic cancer cells. Hepato-gastroenterology 2007; 54:2129-2133.
26. Puzio-Kuter AM, Castillo-Martin M, Kinkade C, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23:675-680. This study is the first one trying to elucidate the mTOR inhibitor effect through molecular pathways modulation.
27. Al Ghonaim M, Habib-ur-Rahman AI, Suwaida A, et al. Post kidney transplant transitional cell carcinoma of bladder. Saudi J Kidney Dis Tranplant 2009; 20:505-512.
28. Einollahi B, Simforoosh N, Lessan-Pezeshki M, et al. Genitourinary tumor following kidney transplantation: A multicenter study. Transplant Proc 2009; 41:2848-2849. This article is an attractive multicentre report of genitourinary neoplasm within renal transplant recipient population.
29. Neuzillet Y, Cabaniols L, Karam G, et al. Study of urothelial bladder tumors in renal transplant recipients. Prog Urol 2006; 16:343-346.
30. Palou J, Angerri O, Sgarra J, et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003; 76:1514-1516.
31. Tillou X, Raynal G, Limani K, et al. Carcinoma in situ in bladder and urethra among renal transplanted patient failure of BCG therapy. Prog Urol 2008; 18:1097-1099.
32. Stenzl AS, Poessler WR, Fradet YF et al. Hexvix fluorescence improves detection and resection of papillary bladder cancer and reduces early recurrence: A multicentre, prospective, randomized study [abstract]. Presented at 24th Annual European Association of Urology Congress; Stockholm, Sweden; 17-21 March 2009.
33. Babjuk M. What is the optimal treatment strategy for T1 bladder tumors? Eur Urol 2010; 57:32-34.
34. Witjes JA, Palou J, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with nonmuscle-invasive bladder cancer: Review of the evidence and recommendations. Eur Urol 2010; 57:607-614.
35. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176:2414- 2422.
36. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology 1997; 50:525-528.
37. Morales JM, Campistol JM, Kreis H, et al. Sirolimus-based therapy with or without cyclosporine: Long-term follow-up in renal transplant patients. Transplant Proc 2005; 37:693-696.
38. Wang SM, Tai HC, Chueh SC, et al. Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients. Transplant Proc 2008; 40:2395-2396.